RT Journal Article
T1 Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum.
A1 Herdick, Meret
A1 Dyrba, Martin
A1 Fritz, Hans-Christian J
A1 Altenstein, Slawek
A1 Ballarini, Tommaso
A1 Brosseron, Frederic
A1 Buerger, Katharina
A1 Can Cetindag, Arda
A1 Dechent, Peter
A1 Dobisch, Laura
A1 Duezel, Emrah
A1 Ertl-Wagner, Birgit
A1 Fliessbach, Klaus
A1 Dawn Freiesleben, Silka
A1 Frommann, Ingo
A1 Glanz, Wenzel
A1 Dylan Haynes, John
A1 Heneka, Michael T
A1 Janowitz, Daniel
A1 Kilimann, Ingo
A1 Laske, Christoph
A1 Metzger, Coraline D
A1 Munk, Matthias H
A1 Peters, Oliver
A1 Priller, Josef
A1 Roy, Nina
A1 Scheffler, Klaus
A1 Schneider, Anja
A1 Spottke, Annika
A1 Jakob Spruth, Eike
A1 Tscheuschler, Maike
A1 Vukovich, Ruth
A1 Wiltfang, Jens
A1 Jessen, Frank
A1 Teipel, Stefan
A1 Grothe, Michel J
K1 Alzheimer’s Disease
K1 Cholinergic Basal Forebrain
K1 Functional Connectivity
K1 Mean Diffusivity
K1 Resting-state fMRI
K1 Subjective Cognitive Decline
AB Dysfunction of the cholinergic basal forebrain (cBF) is associated with cognitive decline in Alzheimer's disease (AD). Multimodal MRI allows for the investigation of cBF changes in-vivo. In this study we assessed alterations in cBF functional connectivity (FC), mean diffusivity (MD), and volume across the spectrum of AD. We further assessed effects of amyloid pathology on these changes. Participants included healthy controls, and subjects with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or AD dementia (ADD) from the multicenter DELCODE study. Resting-state functional MRI (rs-fMRI) and structural MRI data was available for 477 subjects, and a subset of 243 subjects also had DTI data available. Differences between diagnostic groups were investigated using seed-based FC, volumetric, and MD analyses of functionally defined anterior (a-cBF) and posterior (p-cBF) subdivisions of a cytoarchitectonic cBF region-of-interest. In complementary analyses groups were stratified according to amyloid status based on CSF Aβ42/40 biomarker data, which was available in a subset of participants. a-cBF and p-cBF subdivisions showed regional FC profiles that were highly consistent with previously reported patterns, but there were only minimal differences between diagnostic groups. Compared to controls, cBF volumes and MD were significantly different in MCI and ADD but not in SCD. The Aβ42/40 stratified analyses largely matched these results. We reproduced subregion-specific FC profiles of the cBF in a clinical sample spanning the AD spectrum. At least in this multicentric cohort study, cBF-FC did not show marked changes along the AD spectrum, and multimodal MRI did not provide more sensitive measures of AD-related cBF changes compared to volumetry.
YR 2020
FD 2020-11-11
LK http://hdl.handle.net/10668/16908
UL http://hdl.handle.net/10668/16908
LA en
DS RISalud
RD Apr 15, 2025